1
Cywin Charles, Pullen Steven S, Roth Gregory Paul, Snow Roger John, Fleck Roman Wolfgang, Takahashi Hidenori, Winters Michael, Qiao Lei, Nemoto Peter Allen, Moriarity Kevin J, Wang Ji, Bentzien Joerg, Cook Brian, Lo Ho Yin: Substituted benzimidazole compounds. Boehringer Ingelheim Pharmaceuticals, RAYMOND Robert P, February 19, 2004: WO/2004/014905 (8 worldwide citation)

Disclosed are substituted benzimidazole compounds of formula (I) wherein R¿1?, R¿2?, R¿3?, R¿4? and X¿a? are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders an ...


2

3
Baker Stephen Richard, Sapino Chester Jr, Roth Gregory Paul: 3-fluorosulfonyloxyceph-3-em displacement process.. Squibb Bristol Myers Co, June 12, 1991: EP0431794-A2 (2 worldwide citation)

3-Fluorosulfonyloxyceph-3-ems having a protected amino or acylamino group in the 7-position are subject to carbon-carbon bond formation at the 3-position by means of a palladium catalyzed coupling reaction with substituted organostannanes. A process for preparing cefprozil is disclosed.


4
Gao Donghong Amy, Goldberg Daniel R, Hammach Abdelhakim, Hao Ming Hong, Moss Neil, Qian Kevin Chungeng, Roth Gregory Paul, Sarko Christopher Ronald, Swinamer Alan David, Xiong Zhaoming, Kamhi Victor Marc: Derives damides heterocycliques utilises en tant quinhibiteurs de cytokine, Heterocyclic amide derivatives as cytokine inhibitors. Boehringer Ingelheim Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Fetherstonhaugh & Co, June 14, 2011: CA2478232

Disclosed are amide compounds of formula (I) wherein Ar1, Q, Y and R3-R6 of formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic in ...


5

6
Barbosa Antonio J M Jr, Goldberg Daniel R, Hammach Abdelhakim, Liu Pingrong, Moss Neil, Ralph Mark Stephen, Roth Gregory Paul, Sarko Christopher Ronald, Soleymanzadeh Fariba, White Andre: Benzimidazolones and their use as cytokine inhibitors. Boehringer Ingelheim Pharma, June 15, 2005: EP1539708-A1

Disclosed are benzimidazolone compounds of formulas (II) wherein X is O, S or NR5. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also ...


7
Roth Gregory Paul, Qiao Lei, Moriarty Kevin J: 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders. Boehringer Ingelheim Pharmaceuticals, Roth Gregory Paul, Qiao Lei, Moriarty Kevin J, MORRIS Michael P, August 4, 2005: WO/2005/070420

Disclosed are ketone substituted benzimidazole compounds of formula (I) wherein R1, R2, R3, R4 and Xa are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and a ...


8
Gao Donghong Amy, Goldberg Daniel R, Hammach Abdelhakim, Hao Ming Hong, Moss Neil, Qian Kevin Chungeng, Roth Gregory Paul, Sarko Christopher Ronald, Swinamer Alan David, Xiong Zhaoming, Kamhi Victor Marc: Heterocyclic amide derivatives as cytokine inhibitors. Boehringer Ingelheim Pharmaceuticals, RAYMOND Robert P, October 23, 2003: WO/2003/087085

Disclosed are amide compounds of formula (I) wherein Ar1, Q, Y and R3-R6 of formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic in ...


9
Barbosa Antonio Jm Jr, Goldberg Daniel R, Hammach Abdelhakim, Liu Pingrong, Moss Neil, Ralph Mark Stephen, Roth Gregory Paul, Sarko Christopher Ronald, Soleymanzadeh Fariba, White Andre: Benzimidazolones and their use as cytokine inhibitors. Boehringer Ingelheim Pharmaceuticals, RAYMOND Robert P, March 25, 2004: WO/2004/024699

Disclosed are benzimidazolone compounds of formulas (II) wherein X is O, S or NR5. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also ...


10
Cywin Charles, Lee Jinbo, Roth Gregory Paul, Sarko Christopher Ronald, Snow Roger John, Wilson Noel Stewart, Pullen Steven S: Benzimidazoles useful as protein kinase inhibitors. Boehringer Ingelheim Pharmaceuticals, RAYMOND Robert P, May 22, 2003: WO/2003/041708

Disclosed are substituted benzimidazole compounds of formula (I) wherein R¿1?, R¿2?, R¿3?, R¿4? and X¿a? are defined herein. The compounds of the invention are useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclo ...